The Motley Fool··Jonathan PoncianoRedmile Group Doubles Down on Nurix With $63M Investment Despite Underperformance
Redmile Group adds $63M to Nurix stake despite stock decline, betting on promising BTK degrader clinical data and upcoming registrational trials.
NRIXKRYSstock underperformanceclinical trial